North American Society For Pediatric Gastroenterology, Hepatology & Nutrition

At NASPGHAN 2024, Okuno shared findings on reduced parental stress after children’s tube weaning, emphasizing the potential for new outpatient weaning protocols.

HCPLive spoke with Okuno at NASPGHAN 2024 about a study examining changes in parent stress levels and mental health symptoms after a child completes weaning off tube feeding.

At NASPGHAN, HCPLive spoke with Margolis about her team’s study on the link between maternal SSRI exposure and an infant’s development of gut-brain interaction disorders.

Maternal SSRI use was linked to a higher risk of constipation in infants, while untreated maternal depression was tied to colic. Margolis discussed these findings at NASPGHAN.

Silberg urges wider physician education on celiac screening, stressing that guidelines must reach primary care to address disparities and misconceptions.

A study presented at NASPGHAN 2024 found only 10% of eligible kids were screened for celiac disease. Debra Silberg, MD, PhD, urges unbiased, consistent screening.

Research presented at NASPGHAN 2024 found most children with chronic hepatitis C had neurodevelopmental disorders, highlighting the need for proactive care.

A Q&A with a pediatric gastroenterologist on new data detailing trends in water bead injuries in the US from 2013 through 2023.

PEDFIC data at NASPGHAN 2024 show mild, transient diarrhea events with odevixibat for cholestatic pruritus in PFIC, resolving in most cases.

A 10-year study reveals a surge in water bead injuries in young children, with an increase in cases requiring surgical intervention for bowel obstructions.

At NASPGHAN 2024, Collen told HCPLive the promising early data of advanced combination therapy for pediatric refractory IBD although hurdles exist.

Meta-analysis of 30 studies highlights serum markers as prognostic tools for liver survival post-portoenterostomy in biliary atresia.

HCPLive spoke to Collen at NASPGHAN 2024 about early research on environmental exposures prevalent in children with Crohn’s Disease.

Linaclotide trial shows effective constipation relief for pediatric patients with neurodevelopmental disorders, with high treatment adherence and safety profile.

New data from the UNOS database presented at NASPGHAN 2024 details characteristics and outcomes of pediatric liver transplant patients receiving machine perfused organs.

NASPGHAN 2024 data suggests children and adolescents with a history of COVID-19 were twice as likely to develop IBS during the follow-up period.

At NASPGHAN 2024, Sadaka shared results of a study demonstrating the factors associated with a longer hospital stay for children with gastroparesis.

Post-hoc analysis of EoE KIDS trial shows dupilumab benefits for pediatric eosinophilic esophagitis, effective in patients with prior therapy limitations.

HCPLive spoke to Sadaka at NASPHAN 2024 about the increase in hospital admissions among children with gastroparesis after the COVID-19 pandemic.

At NASPGHAN 2024, HCPLive spoke to Shameem about his study on inpatient outcomes of pediatric patients with IBD and GAD vs patients without GAD.

Although children on baclofen had numerically greater improvements in rumination syndrome symptoms than those on placebo, the group difference was insignificant.

Though rare, pediatric colon cancer often presents in advanced stages—emphasizing the need for awareness of risk factors and the opportunities borne from timely intervention.

The role of psychiatric care may be understated in treating IBD in children and adolescents nearing adult age.

Slight differences in disease presentation, as well as navigating the safety discussion with parents, presents unique recommendations for pediatricians initiating invasive imaging.

Data show how care providers shifted their mindsets to prioritize efficacy, safety, tolerability and availability factors during the 2022 formula supply shortage and recall crises.

The optimization of diet and nutrition support during pediatric patients’ rehabilitation is a strategy in lieu of a comprehensively ideal guideline and requires an appreciation for the individual.

Maralixibat and odevixibat have been "game changers" for their benefit in pruritus, and clinicians are interested to learn more about their long-term hepatic benefit.

New data show a promising machine learning tool could help specialists detect fistula risks and provide more tailored, timely care in children.

A number of systemic, industry-based and cultural factors are driving an underrepresentation of minorities in clinicals.

Specialists are hindered by limited therapies and a lack of noninvasive testing methods. Martinez shares a wishlist for her colleagues.